A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes by Dorkhan, Mozhgan & Frid, Anders
Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Type 2 diabetes (T2D) is a progressive disorder with a consistent and steady increase 
in glycosylated hemoglobin (HbA1c) over time associated with enhanced risk of micro- and 
macrovascular complications and a substantial reduction in life expectancy. There are three 
major pathophysiologic abnormalities associated with T2D: impaired insulin secretion, excessive 
hepatic glucose output, and insulin resistance in skeletal muscle, liver, and adipose tissue. These 
defects have been treated in clinical praxis by use of oral insulin secretagogues (sulfonylureas/
glinides) or insulin, biguanides, and thiazolidinediones (TZDs) respectively. Pioglitazone HCL 
is an insulin sensitizer in the TZD family and glimepiride is an insulin secretagogue in the SU 
family. This article reviews mechanisms of action and clinical data behind the use of these two 
commonly used oral hypoglycemic agents with documented efﬁ  cacy and good safety proﬁ  le of 
once-daily administration, alone or in combination with insulin or metformin, in the manage-
ment of T2D in terms of glycemic and non-glycemic effects, tolerability and side effects, and 
impact on vascular health.
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Search criteria
Studies were obtained from searches of databases MEDLINE, Cochrane Data-
base of Systematic Reviews, and Cochrane Central Register of Controlled Trials, 
using search terms; type 2 diabetes, pioglitazone, glimepiride, sulfonylureas, and 
thiazolidinediones limiting for English language. The last search was conducted 
in March 2007.
Mechanisms of action
Thiazolidinediones
Thiazolidinediones (TZDs) are agonists of peroxisome-proliferator activated recep-
tors γ (PPARγ) (Lehmann et al 1995; Henry 1997), which are nuclear receptors, com-
posed of three major isoforms (α, β/δ, and γ). PPARγ is a transcription factor, when 
activated by TZDs, promoting transcription of insulin-sensitive genes involved in 
fatty acid and glucose uptake and lipogenesis and thereby enhance or partially mimic 
selective actions of insulin (Saltiel and Olefsky 1996). PPARγ is also essential for 
normal adipocyte differentiation and proliferation (Lemberger et al 1996). PPARγ is 
expressed in key target tissues for insulin action, most abundantly in adipose tissue 
but also in skeletal muscle, liver, pancreatic β-cells, vascular endothelium, and macro-
phages (Dubois et al 2000; Willson et al 2001). The glucose-lowering effect of TZDs 
is attributed to increased peripheral glucose disposal (Nolan et al 1994; Miyazaki et al 
2001a, b; Miyazaki et al 2002a) and decreased hepatic glucose output (Miyazaki et al 
2001a). There is also evidence of increased insulin secretory response in subjects 
with type 2 diabetes (T2D) following treatment with TZDs (Miyazaki et al 2002b; 
Wallace et al 2004), and a recent in vitro study of acute effects of the PPARγ agonist Vascular Health and Risk Management 2006:2(4) 465–475
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1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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pioglitazone on human islets from subjects both without 
and with T2D suggests that short-term pretreatment with 
pioglitazone primes both healthy and diabetic human islets 
for enhanced glucose-sensitive insulin secretion (Zhang et 
al 2006). TZDs have been shown to cause redistribution of 
fat from hepatic and visceral adipose tissue to subcutaneous 
adipose tissue (Miyazaki et al 2002a; Shadid and Jensen 
2003; Rasouli et al 2005; Smith et al 2005), and in this way 
possibly saving tissues such as liver, skeletal muscle, and 
pancreatic β-cells from lipotoxicity.
Two TZDs are currently approved for treatment of hyper-
glycemia in T2D, rosiglitazone and pioglitazone, which are 
both potent and highly selective agonists for PPARγ, being 
very similar in mechanism of action, effect on hyperglycemia, 
and side effect proﬁ  les. It is important to keep in mind that 
these drugs need insulin as a co-factor for PPAR agonism 
(Feinglos and Bethel 1998), and if used at late stages of T2D, 
when insulinopenia has already developed, the full effect 
cannot be expected.
Pioglitazone HCL is a PPARγ agonist that increases 
both insulin-stimulated glucose uptake in peripheral 
tissues (Miyazaki et al 2001b) and insulin sensitivity 
in hepatic and adipose tissue (Kawamori et al 1998; 
Miyazaki et al 2004), thereby lowering plasma glucose 
both as single agent and in combination with other oral 
hypoglycemic agents (OHA) and/or insulin (Aronoff et al 
2000; Rosenblatt et al 2001; Scherbaum and Goke 2002; 
Herz et al 2003). Pioglitazone has also been shown to have 
multiple beneﬁ  cial effects on lipid metabolism (Winkler
et al 2003; Khan et al 2004; Perez et al 2004; Betteridge 
and Verges 2005; Goldberg et al 2005), endothelial function 
(Forst et al 2005b; Martens et al 2005), atherogenesis 
(Langenfeld et al 2005; Mazzone et al 2006), ﬁ  brinolysis 
(Derosa et al 2005b), and immune function (Marx et al 2000; 
Gosset et al 2001; Martens et al 2006).
Pioglitazone has in addition shown some minor activation 
of PPARα (Forman et al 1995; Lehmann et al 1995). This 
activation has been linked to lowering of plasma triglyceride 
(TG) levels. PPARα activation is also known to have anti-
inﬂ  ammatory effects and preventive effect on arteriosclerosis 
(Rubins et al 1999; Duez et al 2002).
Sulfonylureas
Sulfonylureas (SUs) are widely used drugs in the treatment 
of T2D. They exert their insulin-releasing effect mainly 
by inhibiting ATP-sensitive potassium channels. In the 
pancreatic β-cell this action induces depolarization of 
the cell membrane, allowing an inﬂ  ux of calcium in the 
cell. This in turn induces insulin release into the blood 
(Ashcroft and Rorsman 1989). The insulin release is not 
modiﬁ  ed by plasma glucose and the SU action can thus 
induce hypoglycemia.
It is, however, also evident that SUs have insulin-
releasing effects independent of ATP-sensitive potassium 
channels. Tolbutamide, glibenclamide, and glipizide were 
shown to increase insulin secretion in human β-cells also 
when the membrane of the β-cell was voltage-clamped and 
thus Ca-ﬂ  ux was unaffected (Eliasson et al 1996). It was 
also suggested that this action was mediated by protein 
kinase C (PKC), since the stimulatory action of tolbutamide 
was abolished by a PKC inhibitor. Recent studies of rat 
β-cells have shown that glibenclamide inhibits activity 
of carnitine palmitoyltransferase 1 (CPT 1) which in turn 
switches fatty acid catabolism to synthesis of PKC-activating 
lipids and CPT 1 may thus play a major role in SU-mediated 
insulin release (Lehtihet et al 2003). In this context it is also 
interesting to note that it was shown long ago (Hellman et al 
1984) that glibenclamide accumulates in the β-cell during 
chronic treatment.
ATP-sensitive potassium channels are not speciﬁ  c to the 
pancreatic β-cell but found in a variety of cells throughout 
the human organism. These cells include vascular smooth 
muscle cells (Quayle et al 1997) vascular endothelium, car-
diac myocytes (Nichols and Lederer 1991) and some brain 
neurons (Yamada et al 2001). ATP-sensitive potassium chan-
nels are also found on the inner membranes of mitochondria 
(Dahlem et al 2004). In all mentioned cell types, opening 
of KATP channels in response to metabolic stress leads to 
inhibition of electrical activity and are in that way involved 
in the response of both cardiac and cerebral ischemia. The 
K channels consist of two entities: Kir6 (belonging to the 
family of inwardly rectifying K+ (Kir) channels) and a SU 
receptor, SUR. There is more than one isoform of both Kir6 
(Kir6.1, Kir6.2) and SUR (SUR1, SUR2A, SUR2B) (Proks 
et al 2002). Kir6 and SUR are associated in different ways 
in body tissues and show different sensitivity to various 
K blockers. It is well established that SU can block ATP-
sensitive potassium channels also in cells outside the pan-
creas. It has been proposed that ischemic preconditioning is a 
mechanism of protection against myocardial ischemia. It has 
been described as an adaptive response of the myocardium to 
repeated episodes of ischemia and the proposed mechanism is 
an opening of ATP-sensitive potassium channels in the mito-
chondria. The blocking of potassium channels in the heart 
by SU medication has given rise to a long-standing concern 
regarding the potential adverse effects of SU medication in Vascular Health and Risk Management 2006:2(4) 465–475
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1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
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Pioglitazone and glimepiride in type 2 diabetes
the event of ischemic heart disease. See below for a review 
of existing data.
Clinical trials
Pioglitazone HCL in treatment of T2D
Effect on plasma glucose, insulin sensitivity and lipids
Pioglitazone 7.5–45 mg daily has been compared with 
placebo in several randomized, double blind, parallel-group 
studies in patients with T2D. Pioglitazone 15, 30, and 45 mg 
produced signiﬁ  cant improvements in HbA1c and fasting 
plasma glucose (FPG). Mean change in HbA1c from baseline 
ranged from –0.3% to –1.8% and up to –2.6% when adjusted 
for difference from placebo. Pioglitazone also produced 
signiﬁ  cant decreases in TG and signiﬁ  cant increases in high 
density lipoprotein (HDL) (Aronoff et al 2000; Rosenblatt 
et al 2001; Scherbaum and Goke 2002; Herz et al 2003).
In comparative/combination trials with metformin, in a 
1-year, active-comparator trial, patients poorly controlled with 
SU were randomly assigned to metformin or pioglitazone. 
Both treatments resulted in comparable reductions in HbA1c 
and FPG with sustained glycemic control throughout the 
study (Hanefeld et al 2004). In a combination trial metformin 
plus pioglitazone 30 mg was compared with metformin plus 
placebo in patients with poorly controlled T2D. Treatment 
with pioglitazone 30 mg plus metformin resulted in 
signiﬁ  cant improvement in HbA1c and FPG compared with 
placebo plus metformin. In addition, patients treated with 
metformin plus pioglitazone had a signiﬁ  cant reduction 
in TG and a signiﬁ  cant increase in HDL-C compared with 
metformin plus placebo (Einhorn et al 2000). During two 
active-comparator trials, treatment with metformin and 
pioglitazone resulted in equal, significant reduction in 
HbA1c while insulin sensitivity measured by homeostasis 
model assessment showed signiﬁ  cant improvement in the 
pioglitazone, but not the metformin group at 32 weeks (Pavo 
et al 2003; Schernthaner et al 2004b).
In comparative/combination trials with SUs, pioglitazone 
produced comparable reduction in HbA1c and FPG as SU. 
Pioglitazone produced a slower but sustained reduction in 
HbA1c compared with an earlier effect in the SU treated 
group. Insulin sensitivity measured by homeostasis model 
assessment showed signiﬁ  cantly greater improvement during 
pioglitazone treatment (Tan et al 2004a, b). In combination 
trials, pioglitazone produced signiﬁ  cant additional improve-
ment in glycemic control, as measured by FPG and HbA1c. 
Secondary efﬁ  cacy measures, including TG and HDL, also 
showed signiﬁ  cant improvement after adding pioglitazone 
to SU (Kipnes et al 2001; Hanefeld et al 2004).
Improvement in HbA1c was sustained throughout the 
double-blind phase and for 72 and 104 weeks in 2 open-label 
extension trials when combining pioglitazone with metformin 
or glibenclamide (Einhorn et al 2000; Tan et al 2004b).
Both pioglitazone and rosiglitazone are also approved 
for triple combination with metformin and a SU, produc-
ing signiﬁ  cant additional decrease in HbA1c and seem to 
be equally effective (Balfour and Plosker 1999; Gillies and 
Dunn 2000; Tran et al 2006).
In combination/comparative trials of pioglitazone and 
insulin, pioglitazone, when added to stable insulin regimens, 
signiﬁ  cantly improved HbA1c and FPG in patients with T2D. 
Pioglitazone treatment also provided signiﬁ  cant beneﬁ  t with 
respect to plasma HDL and TG levels and was as effective as 
a single injection of NPH at bedtime (Rosenstock et al 2002; 
Aljabri et al 2004; Mattoo et al 2005; Davidson et al 2006).
Side effects
During clinical trials, adverse events have been mild to 
moderate in severity with an overall frequency of adverse 
events being similar across the treatment groups (pioglitazone 
vs metformin, SU, or insulin). Adverse event proﬁ  les were 
different between treatment groups. During treatment with 
pioglitazone, edema and weight gain were reported more 
frequently, whereas gastrointestinal adverse events were 
reported more frequently in the metformin group. Hypogly-
cemia occurred at a higher incidence in patients treated with 
a SU or insulin (Aljabri et al 2004; Schernthaner et al 2004b; 
Charbonnel et al 2005; Belcher et al 2005; Jain et al 2006). 
There were no signs of hepatotoxicity in these studies. On 
the contrary there was a decrease in liver enzymes which also 
has been shown in other studies (Dorkhan et al 2006) and in 
the DREAM study with rosiglitazone (Gerstein et al 2006). 
Interestingly, several pilot trials have consistently shown 
positive effects of TZDs in the treatment of nonalcoholic 
steatohepatitis (NASH) (Caldwell et al 2001; Neuschwander-
Tetri et al 2003; Sanyal et al 2004; Tiikkainen et al 2004) and 
Belfort et al reported recently in a placebo-controlled trial that 
administration of pioglitazone led to metabolic and histologic 
improvement in subjects with NASH (Belfort et al 2006). 
However, an increase in incidence of heart failure (Dormandy 
et al 2005) and bone loss in older women (Kahn et al 2006; 
Schwartz et al 2006) are the greatest matters of concern with 
TZDs at present, warranting further investigation.
Potential cardiovascular effects of pioglitazone HCL
As monotherapy or in combination with SU, metformin, or 
insulin, pioglitazone has shown consistent improvements in Vascular Health and Risk Management 2006:2(4) 465–475
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1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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TG and HDL levels with no signiﬁ  cant effect on total or LDL 
cholesterol, the greatest degree of improvement occurring at 
the highest dosage in most cases. These changes ranged from 
about a 16% decrease in TG to a 12%–19% increase in HDL 
(Aronoff et al 2000; Rosenblatt et al 2001; Scherbaum and 
Goke 2002; Herz et al 2003). Treatment with pioglitazone 
seems to be associated with greater beneﬁ  cial effects on 
blood lipid levels than treatment with rosiglitazone (Boyle 
et al 2002; Goldberg et al 2005). Pioglitazone also has shown 
to reduce dense LDL signiﬁ  cantly and independently from 
fasting triglycerides and HDL cholesterol, suggesting the 
antiatherogenic potential of pioglitazone may be greater 
than that expected from its effects on triglycerides, LDL, 
and HDL cholesterol alone (Winkler et al 2003). In a study 
by Berhanu et al, there was marked improvements in lipid 
proﬁ  les in terms of LDL particle size and apolipoproteins 
after treatment conversion from rosiglitazone to pioglitazone 
in patients with T2D (Berhanu et al 2006).
There is some evidence on beneﬁ  cial effect of TZDs on 
hypertension in patients with (Fullert et al 2002; Gerber et al 
2003; Fukuen et al 2005; Derosa et al 2005a; IRIS 2007; 
Dormandy et al 2005) and without T2D (Fullert et al 2002).
TZDs have also been shown to increase adiponectin 
levels, which are reduced in obesity and negatively correlated 
to insulin resistance and development of arteriosclerosis 
(Forst et al 2005a; Pfutzner et al 2005a; Dorkhan et al 2006). 
However, the mechanism is not well understood yet but a 
recent study proposed that increased adiponectin production 
by pioglitazone was mediated through suppression of SOCS3 
expression, playing an important role in improved insulin 
sensitivity (Kanatani et al 2007).
In other studies there have been evidences of reduction, 
regression or slowing progression of carotid intima media 
thickness (CIMT) (Nakamura et al 2004; Langenfeld et al 
2005; Mazzone et al 2006) in patients with T2D when treated 
with pioglitazone as well as reduced neointimal tissue 
proliferation after coronary stent implantation and reduced 
in-stent restenosis (Takagi et al 2003; Marx et al 2005; Nishio 
et al 2006). The study by Mazzone et al was a randomized, 
double-blind, comparator-controlled, multicenter trial 
including 462 adults with T2D, comparing effect of 
pioglitazone vs glimepiride on CIMT during 18 months of 
treatment. The change in CIMT was less with pioglitazone 
vs glimepiride, and pioglitazone slowed progression of 
maximum CIMT compared with glimepiride similarly across 
prespeciﬁ  ed subgroups based on age, sex, systolic blood 
pressure, duration of diabetes, body mass index, HbA1c 
value, and statin use. In a pioneer study there was speciﬁ  c 
evidence of anti-inﬂ  ammatory and antiatherogenic effect of 
pioglitazone versus glimepiride in terms of reduction in high-
sensitiveity C-reactive protein, matrix metalloproteinase, and 
monocyte chemoattractant protein, independent of glycemic 
control (Pfutzner et al 2005b).
Data from several animal and human studies support the 
notion that TZDs even reduce urine albumin excretion and 
may prevent development of renal injury. There is, however, 
a relative lack of evidence demonstrating the effects of 
TZDs on hard renal outcomes as reviewed by Saraﬁ  dis and 
Bakris (2006) and there is need for studies with the particular 
objective of possible renoprotective effect of TZDs.
The PROspective pioglitAzone Clinical Trial In macro-
Vascular Events (PROactive) study was the ﬁ  rst randomized, 
double-blind outcome study in patients with T2D managed 
with diet and/or oral blood glucose-lowering drugs and/or 
insulin who had a history of macrovascular disease, assessing 
the effect of pioglitazone on the secondary prevention of mac-
rovascular events. A total of 5238 patients were randomized 
with the cohort of patients, a typical type 2 diabetic popula-
tion at high risk of further macrovascular events. The results 
were presented in 2005 after an average time of observation 
of 34.5 months. Treatment with pioglitazone reduced the 
secondary endpoint of combined all-cause mortality, non-
fatal myocardial infarction, and stroke by 16% (Dormandy 
et al 2005), at the expense of increased heart failure (Yki-
Jarvinen 2005). A recently published subgroup analysis from 
PROactive demonstrated that pioglitazone reduced the risk 
of recurrent stroke signiﬁ  cantly in high-risk patients with 
T2D (Wilcox et al 2007).
Glimepiride in treatment of T2D
Effect on plasma glucose
Two systematic reviews on the effects and side effects of 
glimepiride (Campbell 1998; Inzucchi 2002) have been 
helpful in identifying randomized controlled trials (RCTs). 
Draeger et al (1996) found equivalent reductions in HbA1c 
after 12 months’ treatment with glimepiride (1–8 mg) or 
glibenclamide (2.5–20 mg) after titration to a common target. 
End mean HbA1c in the glimepiride group was 8.4% and in 
the glibenclamide group 8.3%. The study was conducted 
in 1044 patients with T2D aged 26–81 years. All patients 
were previously treated with glibenclamide for 2 months; 
half the study population was thus transferred to treatment 
with glimepiride and half remained on glibenclamide. 
The purpose of the study was to show non-inferiority of 
glimepiride vs glibenclamide. Another RCT (Dills and 
Schneider 1996) studied 577 patients, mean age 59.5 years, Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Pioglitazone and glimepiride in type 2 diabetes
with type 2 diabetes previously treated with diet or any SU. 
No signiﬁ  cant difference in HbA1c was found at 52 weeks 
after treatment with glimepiride 1–12 mg or glibenclamide 
1.25–15.00 mg titrated to pre-determined targets. HbA1c was 
reduced from 8.50 ± 1.20% (mean ± SD) at baseline to 8.24 ± 
1.51% for glimepiride and from 8.50 ± 1.30% at baseline 
to 8.28 ± 1.48% for glibenclamide. Also in this study the 
main objective was to show non-inferiority of glimepiride 
compared with glibenclamide.
One study was found (Schernthaner et al 2004a) that 
compared adding modiﬁ  ed release gliclazide (gliclazide 
MR) 30–120 mg or glimepiride 1–6 mg daily to current 
treatment (diet alone, metformin, or acarbose) in 845 
patients with type 2 diabetes. It found no significant 
difference in HbA1c at 27 weeks between gliclazide MR 
and glimepiride. HbA1c decreased similarly in both groups, 
from 8.4% to 7.2% on gliclazide MR and from 8.2% to 
7.2% on glimepiride.
Several RCTs have been compared glimepiride with 
placebo as therapy added to lifestyle changes in drug-
naive patients. In one such study (Luis Bautista et al 2003) 
glimepiride 1–4 mg (n = 48, mean age 48.4) or placebo 
(n = 22, mean age 50.7) was added to diet/exercise advice 
in Mexican Americans. Not surprisingly the HbA1c reduction 
from baseline to end-point was statistically signiﬁ  cant in 
favor of glimepiride after 14 weeks.
Side effects
Rosenstock et al (1996) reported no episodes of hypogly-
cemia (p-glucose <3.3 mmol/L) with either glimepiride 
8–16 mg/day or placebo during a 14-week study in 416 
patients previously treated with any drug in monotherapy. 
Luis Bautista et al (2003) found no signiﬁ  cant difference in 
self-assessment of hypoglycemia reported over 14 weeks 
between patients taking glimepiride 1–4 mg or placebo and 
no conﬁ  rmed episodes of hypoglycemia (plasma glucose 
<3.1 mmol/L). The weight gain was signiﬁ  cantly higher in 
the glimepiride group compared with the placebo group.
Draeger et al (1996) found a lower incidence of 
hypoglycemia in people treated with glimepiride 1–8 mg 
compared with glibenclamide 2.5–20 mg. The incidence 
was 60 episodes with glimepiride and 74 episodes with 
glibenclamide. The effect on HbA1c was the same in 
both groups, as reported above. The study by Dills and 
Schneider (1996) found a lower incidence of symptomatic 
hypoglycemia (12% and 17% respectively) in people treated 
with glimepiride 1–12 mg compared with glibenclamide 
1.25–15.00 mg over 12 months.
Potential cardiovascular effects of SUs in general 
and glimepiride in particular
Initial concern for this issue was raised in the early 1970s 
when the University Group Diabetes Program assessed the 
efﬁ  cacy of oral hypoglycemic treatment compared with 
insulin and diet alone in the prevention of cardiovascular 
complications. They demonstrated a signiﬁ  cantly higher car-
diovascular mortality in patients treated with SUs compared 
with diet alone (Prout 1971; Karam et al 1975). The United 
Kingdom Prospective Diabetes Study (UKPDS) attempted to 
answer the question of whether improved glycemic control 
reduced the risk of cardiovascular death in patients who were 
taking insulin or SUs (UKPDS 1998a, b). In that study no 
detrimental effect of SUs was noted, and the UKPDS is often 
cited as evidence that SUs do not increase cardiovascular risk 
to patients with type 2 diabetes. The UKPDS, however, did 
not ascertain the effect these agents had on patients with type 
2 diabetes in the setting of acute coronary syndromes, ie, in 
patients directly at risk of myocardial infarction. The UKPDS 
patients were also newly diagnosed and known cardiovascu-
lar disease was an exclusion criterion; the absolute numbers 
of cardiovascular events were thus low. In a UKPDS substudy 
metformin in monotherapy was found to have a beneﬁ  cial 
impact on cardiovascular events; this effect was not evident 
when SU was used in combination with metformin.
One review (Proks et al 2002) suggests that the SUR1 
subunit of the KATP channel is mainly found in the beta-cell 
and that the SUR2 subunit of the KATP channel is found 
in smooth muscle and cardiac cells. It is further proposed 
that in humans, tolbutamide and gliclazide block channels 
containing SUR1 whereas glibenclamide, glimepiride, and 
repaglinide block both types of channels. It is, however, also 
clear that the inhibition of the KATP channel is not complete 
and that differences appear between drugs. In an extensive 
review (Quast et al 2004) the authors concluded that in 
animal models the coronary vasculature of several species 
respond to glibenclamide with vasoconstriction and a reduc-
tion of coronary blood ﬂ  ow and they also found indications 
in several studies that the vascular KATP channel plays a 
major role in the autoregulation of coronary blood ﬂ  ow in 
the animal and human heart in hypoxia. There has been a 
general lack of knowledge regarding the role of KAPT chan-
nels in the myocardium, the general belief being that the high 
ATP concentrations in the myocyte keep the KAPT chan-
nels closed under normal conditions. In one study, however 
(Zingman et al 2002), it was shown that in mice the knockout 
of Kir6.2 (the ion-conducting subunit of the KAPT channel) 
resulted in impaired cardiac performance during sympathetic Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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stimulation, pointing to a possible role of KAPT channels in 
maintaining cardiac cellular homeostasis not only in response 
to ischemia but also in the adaptive reaction to stress. The 
role of SUs in this context has not been studied.
Glimepiride binds predominantly to a 65 kDa subunit 
protein of the KATP complex while other SUs predominan-
tely bind to a 140 kDa protein (Kramer et al 1994). The clinical 
relevance of these ﬁ  ndings remains to be elucidated.
One study in perfused hearts in rats where coronary 
arteries were occluded by means of a snare (Mocanu et al 
2001) showed that the beneﬁ  cial effect of ischemic pre-
conditioning was completely abolished by including glib-
enclamide in the perfusate but unaffected when including 
glimepiride. Other studies in animals (Geisen et al 1996) 
have also shown that glimepiride produced less cardiovas-
cular effect than glibenclamide at equivalent blood glucose 
decrease in rats and dogs. In rabbit ventricular myocytes 
(Sato et al 2006), tolbutamide, gliclazide, and glimepiride 
had no effect on the mitochondrial KATP channel and did 
not affect the (cardioprotective) effects of the KATP-opener 
diazoxide. Glibenclamide on the other hand interfered 
with the effect of diazoxide and the authors concluded that 
glibenclamide interferes with the cellular pathways that 
confer cardioprotection whereas glimepiride, gliclazide, 
and tolbutamide do not.
Data from studies in humans are scarce, for obvious rea-
sons. In one study (Ghosh et al 2001), tissue samples from 
the right atrium were obtained from patients of 7 different 
categories: non-diabetics, patients with type 2 diabetes both 
treated with KATP blockers and diet only, patients with 
type 1 diabetes, and patients with 3 different degrees of 
decreased ejection fraction (EF). Five protocols were used in 
a randomized fashion: 1. Control, incubation in oxygenated 
buffer; 2. Ischemia alone; 3. Preconditioning + ischemia; 
4. Diazoxide + ischemia; 5. Glibenclamide + preconditioning 
+ ischemia. Preconditioning was made by 5-min ischemia/
5-min reoxygenation before a 90-min ischemia/120-min 
reoxygenation. Preconditioning prevented the effects of isch-
emia in all groups except patients with diabetes type 1 and 2 
and those with the lowest EF. Diazoxide prevented effects of 
ischemia in all groups except patients with diabetes type 1 
and 2. Glibenclamide abolished protection in non-diabetics 
and diet-controlled diabetes groups and did not affect dia-
betes type 1 and diabetes type 2 patients treated with KATP 
channel blockers.
One study in healthy male volunteers (Bijlstra et al 
1996) showed that glibenclamide signiﬁ  cantly inhibited the 
diazoxide-induced increase in forearm blood ﬂ  ow compared 
with placebo whereas glimepiride did not. The ﬁ  ndings have 
been questioned in a later review (Riveline et al 2003).
There are a few important studies that try to study the 
role of glimepiride and ischemic preconditioning in real-
life myocardial ischemia. In a double-blind RCT (Klepzig 
et al 1999), 45 predominantly male volunteers were divided 
into 3 groups when performing balloon angioplasty of high 
grade coronary artery stenosis. Each patient underwent
3 dilatations, and drugs were administered between dilatation 
2 and 3. Balloon pressures and time intervals were identical 
in all 3 dilatations. Three drugs were infused intravenously 
in a randomized fashion: placebo, 1 mg glimepiride, or 
2 mg glibenclamide. The primary variable was the mean 
ST segment shift during dilatation. Glimepiride and placebo 
groups showed a statistically signiﬁ  cant reduction of mean 
ST segment shift between dilatation 2 and 3, interpreted as 
ischemic preconditioning. The glibenclamide group showed 
no difference in mean ST segment depression between 
dilatations. Direct comparison of the two drugs showed no 
statistically signiﬁ  cant difference, as the power of the study 
was low.
One study from Taiwan (Lee and Chou 2003) investi-
gated 20 patients with no diabetes and 23 patients with T2D 
when performing coronary angioplasty. The non-diabetic 
patients were given 10 mg glibenclamide (n = 6), 2 mg 
glimepiride (n = 7) or nothing (n = 7) before the angioplasty 
together with a glucose infusion to prevent hypoglycemia. 
No hypoglycemias were reported during the study. Patients 
with diabetes were taking either glimepiride (n = 12) or glib-
enclamide (n = 11). In both groups mean ST segment shift 
decreased between the ﬁ  rst and the second balloon inﬂ  ation 
in the control group and in the group taking glimepiride but 
not in the glibenclamide group. When nicorandil, an agent 
speciﬁ  cally activating mitochondrial KATP channels, was 
given i.v. to patients with diabetes before angioplasty there 
was no difference in mean ST segment shift in the glimepiride 
nor glibenclamide groups.
Combination of pioglitazone HCL 
and glimepiride in treatment of T2D
In vitro studies demonstrate that glimepiride has the potential 
to induce PPAR gamma activity, thereby improving insulin 
resistance (Fukuen et al 2005; Inukai et al 2005).
In a study of long-term effect of TZD on blood pressure 
in diabetic patients with metabolic syndrome treated with 
glimepiride there was signiﬁ  cant improvement in systolic- and 
diastolic blood pressure after 12 months suggesting that the 
addition of a TZD to the glimepiride treatment of patients with Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Pioglitazone and glimepiride in type 2 diabetes
T2D and metabolic syndrome is associated with a signiﬁ  cant 
improvement in the long-term blood pressure control, related 
to a reduction in insulin-resistance (Derosa et al 2005a). In 
a multicenter, randomized, double-blind, controlled clinical 
trial of treatment with pioglitazone or rosiglitazone added to 
glimepiride in patients with T2D and metabolic syndrome, 1 
year of treatment with the pioglitazone combination was asso-
ciated with signiﬁ  cantly reduced plasma lipoprotein (a) levels, 
a known risk factor for cardiovascular disease, compared with 
the rosiglitazone combination (Derosa et al 2006).
Discussion
Diabetes is a strong, independent risk factor for cardiovascu-
lar disease, causing a 2- to 4-fold increase in cardiovascular 
mortality in patients with T2D (Panzram 1987; Stamler et al 
1993; UKPDS 1998a, b; Stratton et al 2000). The two largest 
prospective diabetes studies, the UKPDS and the University 
Group Diabetes Program (UGDP) showed no statistically 
signiﬁ  cant reduction of cardiovascular endpoints through 
improved glycemic control. Both pioglitazone and glimepiride 
are well tolerated and effective in achieving metabolic con-
trol in treatment of patients with T2D, as monotherapy or 
in combination. In spite of massive evidence of beneﬁ  cial 
effects of pioglitazone on conventional and non-conventional 
cardiovascular risk factors, the results from the ﬁ  rst prospec-
tive outcome study (Dormandy et al 2005) are still considered 
controversial and need conﬁ  rmation. The latest Cochrane 
review on the subject has considered 22 RCTs including more 
than 6000 people treated with pioglitazone. They conclude 
that until new evidence becomes available, the beneﬁ  t-risk 
ratio of pioglitazone remains unclear (Richter et al 2006).
There is no doubt that TZDs have contributed to our 
understanding of the pathophysiology of T2D and its treat-
ment but there are still some unresolved issues about heart 
failure that require further study before a positive recommen-
dation regarding their effects on cardiovascular risk reduction 
can be made. In our opinion, it is very important to estimate 
risk vs beneﬁ  t in each individual in order to make appropriate 
therapeutic choices for patients with T2D.
Adequate circulating insulin is a prerequisite for TZD 
activity (Feinglos and Bethel 1998) and should be accounted 
for before initiating therapy, otherwise there is a risk that the 
full effect of TZDs cannot be achieved. For the practising 
physician it is of great interest to have instruments to identify 
individuals at risk of developing heart failure or to monitor 
cardiac function regularly during treatment. Natriuretic 
peptides can be candidates for both identifying individuals 
at risk to develop heart failure and to monitor the effect of 
TZDs on cardiac load, but there are for now no established 
recommendations addressing this issue (Jernberg et al 2004; 
Karthikeyan and Lip 2007). Some recent studies have been 
designed to identify factors associated with TZD effect 
(Phatak and Yin 2006; Wilcox et al 2007) but more studies 
are needed to help draw guidelines for individually adapted 
therapy choices as well as studies on markers of cardiovas-
cular risk speciﬁ  cally. Several ongoing outcome studies are 
to be presented in the near future and these will undoubtedly 
increase our knowledge in this area. All evidence considered, 
it seems fair to conclude that the positive cardiovascular 
effects of TZDs (reduced hyperglycemia, improved dys-
lipidemia, decreased blood pressure, improved endothelial 
function, reduced central obesity, decreased inﬂ  ammation, 
and decreased microalbuminuria) overweigh the negative 
ones (weight gain and increased heart failure).
The development of a new generation of TZDs, the partial 
PPARγ agonists with more speciﬁ  c action, may prove efﬁ  ca-
cious not only in treatment of T2D but also in prevention of 
atherosclerosis.
Glimepiride is a long-acting SU of recent origin. The 
glucose-lowering effects are well documented and compa-
rable with those of other long-acting SUs. There is an ongoing 
controversy regarding SUs and other KAPT channel blockers 
and the risk of adverse effects on the heart. Since patients with 
diabetes have a greatly increased risk of developing and dying 
from cardiovascular disease, it would be appalling if it were 
proven that a remedy used for centuries in fact worsened the 
disease! Few would argue that, in the experimental setting, 
glimepiride can show effects on the heart and vessels that 
distinguishes it from its most common comparator, gliben-
clamide. The discussion has almost exclusively revolved 
around the phenomenon of ischemic preconditioning (IPC), 
described as a protective action taken by a heart subjected to 
a short ischemia and thus alleviating the effects of a longer 
ischemia. The different effects on the heart by the different 
KATP channel blockers result from their different afﬁ  nity to 
SUR1 (mainly β-cell) and SUR2 (mainly heart and vessels) 
subunits of the SU (140K) receptor. The important question 
remains to be answered: do these differences matter in our 
drug-treated T2D patients? This question is clearly very 
difﬁ  cult question to answer, since a prospective RCT is 
almost impossible to perform, but in a prospective study in 
France (Danchin et al 2005) 487 patients with acute myocar-
dial infarction and diabetes were identiﬁ  ed. Among the 215 
patients with previous SU treatment, the in-hospital mortality 
was 10.2% compared with the non-SU (insulin, diet, other 
drugs) group mortality of 16.9% (p = 0.035).Vascular Health and Risk Management 2006:2(4) 465–475
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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The UKPDS remains our most important source of pro-
spective data for risk vs treatment of T2D, and according to 
the UKPDS there is no obvious increase in cardiovascular 
risk when treating T2D with SUs.
On the other hand, it can be argued that if potential 
differences in the beneﬁ  t of glimepiride can be detected in 
the experimental setting and treatments are comparable in 
other ways, we may let this inﬂ  uence our clinical decisions. 
As with the TZDs, we leave this to the discretion and clinical 
judgment of the reader.
Abbreviations
FPG, fasting plasma glucose; HbA1c, glycosylated hemo-
globin; HDL, high density lipoprotein cholesterol; OHA, 
oral hypoglycemic agents; PPARs, peroxisome-proliferator 
activated receptors; RCT, randomized controlled trials; SU, 
sulfonylurea; T2D, type 2 diabetes; TG, triglycerides; TZD, 
thiazolidinedione.
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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